ReVance Therapeutics, Inc. Announces Management Additions; Company Strengthens Clinical, Regulatory And R&D Capabilities
10/19/2005 5:09:19 PM
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--June 22, 2005--Revance Therapeutics announced today the appointment of Mary Spellman, M.D., as Senior Vice President of Clinical Development, Jane A. Moffitt as Senior Vice President of Regulatory Affairs, and Bobby Purkait as Senior Vice President of R&D and Operations.
"Mary, Jane and Bobby each bring leadership skills and successful industry experience with pharmaceuticals, biologics, and a diverse range of therapeutic products to our senior management team," said Dan Browne, president and chief executive officer of Revance Therapeutics. "As we drive our flagship topical botulinum toxin program through the clinical and regulatory process, these executives will play an integral role in Revance's efforts to shift the treatment paradigm for botulinum toxin from injectable to topical formulations for therapeutic indications, as well as developing our product pipeline of compounds for elastin regeneration and fat regression."
comments powered by